HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Equity Bottom-Up

<ul>
<li>The market seems “not excited” with fruquintinib’s FDA approval.We analyzed the potential reasons behind.Beyond boosting market sentiment when license-out deal is announced initially,its practical impact on valuation could be limited.</li>
<li>HUTCHMED’s financial performance is good. The deal with Takeda helps to relieve cash-flow pressure. We think HUTCHMED is a relatively safe bet for investors as eventual breakeven is drawing near.</li>
<li>If based on conservative calculation, market value of about US$1,455-2,055 million is a good place to long.When market value is higher than US$3,500 million, it's time to consider taking profits.</li>
</ul>


The market seems “not excited” with fruquintinib’s FDA approval.We analyzed the potential reasons behind.Beyond boosting market sentiment when license-out deal is announced initially,its practical impact on valuation could be limited.
HUTCHMED’s financial performance is good. The deal with Takeda helps to relieve cash-flow pressure. We think HUTCHMED is a relatively safe bet for investors as eventual breakeven is drawing near.
If based on conservative calculation, market value of about US$1,455-2,055 million is a good place to long.When market value is higher than US$3,500 million, it's time to consider taking profits.


Hutchmed China Ltd (13.HK/​HCM.US) - A Valuable Option in the Portfolio

Blue Lotus China New Economy Research, Blue Lotus Research Institute

Eric Wen

Blue Lotus China New Economy Research

China growth and global non-US Internet equities

Blue Lotus Research Institute

Blue Lotus Research is a Hong Kong Type 4 Licensed investment advisory firm focusing on Chinese growth equities and global non-US Internet equities

Thematic (Sector/Industry)

<ul>
<li>TCOM/HTHT/ATAT: China Tourism - OTA platform DAU remain lackluster, weak year end travel demand (-)</li>
<li>MNSO: Korea’s top dollar store chain Daiso buys out Japanese shareholder (-)</li>
<li>9995HK：Harbour BioMed have signed an exclusive licensing agreement with Pfizer of a mesothelin (MSLN) antibody-drug conjugate (ADC) (-) </li>
</ul>


TCOM/HTHT/ATAT: China Tourism - OTA platform DAU remain lackluster, weak year end travel demand (-)
MNSO: Korea’s top dollar store chain Daiso buys out Japanese shareholder (-)
9995HK：Harbour BioMed have signed an exclusive licensing agreement with Pfizer of a mesothelin (MSLN) antibody-drug conjugate (ADC) (-) 


[Blue Lotus Daily]: TCOM/HTHT/ATAT/MNSO/9995 HK/XPEV

<ul>
<li>9995 HK：Chinese BsAb ADC developer wins US$8.4 billion license out deal from Bristol-Myers Squibb(-)</li>
<li>LKNCY: Luckin Coffee raised subsidy to franchisees in winter season(-)</li>
<li>1211.HK/300750.CH: LGES signs multi-hundred-million dollar contract with Poland electric bus manufacturer(-)</li>
</ul>


9995 HK：Chinese BsAb ADC developer wins US$8.4 billion license out deal from Bristol-Myers Squibb(-)
LKNCY: Luckin Coffee raised subsidy to franchisees in winter season(-)
1211.HK/300750.CH: LGES signs multi-hundred-million dollar contract with Poland electric bus manufacturer(-)


[Blue Lotus Daily]：LKNCY/1211 HK/300750 CH/TSLA/9995 HK

Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

Asia Pac IPO & Placement Research, China biotech

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Quantitative Analysis

<ul>
<li>We analyse the changes of A-H premium on 146 stocks over the last week. The average A-H premium was 129.3% as of Dec 8th.</li>
<li>The average A-H premium changed by 1.8ppt week on week, led by consumer staples, health care, energy and offset by consumer discretionary, utilities.</li>
<li>We highlight weekly changes in A-H premium for CMB, Ping An Insurance, Beigene.</li>
</ul>


We analyse the changes of A-H premium on 146 stocks over the last week. The average A-H premium was 129.3% as of Dec 8th.
The average A-H premium changed by 1.8ppt week on week, led by consumer staples, health care, energy and offset by consumer discretionary, utilities.
We highlight weekly changes in A-H premium for CMB, Ping An Insurance, Beigene.


A-H Premium Weekly (Dec 8th): CMB, Ping An Insurance, Beigene

<ul>
<li>China’s innovative drug sector remains a liquidity driven sector, as investible choices are limited, which include Akeso and BeiGene as our BUY ideas. </li>
<li>We also notice positive change in Innovent but opt to keep rating unchanged;</li>
<li>We upgrade BeiGene from SELL to BUY and maintain SELL on RemeGen, Innovent, JUNSHI and ZaiLab. We discontinued coverage on Legend Biotech.</li>
</ul>


China’s innovative drug sector remains a liquidity driven sector, as investible choices are limited, which include Akeso and BeiGene as our BUY ideas. 
We also notice positive change in Innovent but opt to keep rating unchanged;
We upgrade BeiGene from SELL to BUY and maintain SELL on RemeGen, Innovent, JUNSHI and ZaiLab. We discontinued coverage on Legend Biotech.


[Blue Lotus Sector Update]: Solid Companies Starting to Rise from the Ashes

China

RemeGen Co., Ltd. operates biotechnology businesses. The Company develops therapeutic antibody drugs such as antibody drug conjugates (ADC), antibody fusion proteins, monoclonal antibodies and double antibodies. RemeGen provides solutions autoimmune diseases, tumor diseases, and ophthalmic diseases.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Remegen (9995 HK)

Hutchmed China Ltd (13.HK/HCM.US) - A Valuable Option in the Portfolio

Despite market's lackluster response to fruquintinib’s FDA approval, we're optimistic about HUTCHMED’s outlook.Rich cash flow/future catalysts make...

Xinyao (Criss) Wang

[Blue Lotus Daily]: TCOM/HTHT/ATAT/MNSO/9995 HK/XPEV

China's tourism OTA platform sees low user activity and weak year-end travel demand. Korea's Daiso acquires Japanese shareholder. Harbour BioMed...

Blue Lotus Research Institute

[Blue Lotus Daily]：LKNCY/1211 HK/300750 CH/TSLA/9995 HK

Chinese BsAb ADC developer secures a license deal with Bristol-Myers Squibb. Luckin increases subsidies for franchisees during the winter. LGES...

Blue Lotus Research Institute

A-H Premium Weekly (Dec 8th): CMB, Ping An Insurance, Beigene

We analyzed A-H premium changes in the past week and highlight A-H premium changes for CMB, Ping An Insurance and Beigene.

Ke Yan, CFA, FRM

[Blue Lotus Sector Update]: Solid Companies Starting to Rise from the Ashes

China's drug sector is driven by liquidity, with limited investment choices. Akeso and BeiGene are recommended as buy options, while RemeGen,...

Blue Lotus Research Institute

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Hutchmed China Ltd (13.HK/​HCM.US) - A Valuable Option in the Portfolio

Despite market's lackluster response to fruquintinib’s FDA approval, we're optimistic about HUTCHMED’s outlook.Rich cash flow/future catalysts make...

Xinyao (Criss) Wang

[Blue Lotus Daily]: TCOM/HTHT/ATAT/MNSO/9995 HK/XPEV

​China's tourism OTA platform sees low user activity and weak year-end travel demand. Korea's Daiso acquires Japanese shareholder. Harbour BioMed...

Blue Lotus Research Institute

[Blue Lotus Daily]：LKNCY/1211 HK/300750 CH/TSLA/9995 HK

​Chinese BsAb ADC developer secures a license deal with Bristol-Myers Squibb. Luckin increases subsidies for franchisees during the winter. LGES...

Blue Lotus Research Institute

A-H Premium Weekly (Dec 8th): CMB, Ping An Insurance, Beigene

We analyzed A-H premium changes in the past week and highlight A-H premium changes for CMB, Ping An Insurance and Beigene.

Ke Yan, CFA, FRM

[Blue Lotus Sector Update]: Solid Companies Starting to Rise from the Ashes

​China's drug sector is driven by liquidity, with limited investment choices. Akeso and BeiGene are recommended as buy options, while RemeGen,...

Blue Lotus Research Institute

Hutchmed China Ltd (13.HK/HCM.US) - A Valuable Option in the Portfolio

China's tourism OTA platform sees low user activity and weak year-end travel demand. Korea's Daiso acquires Japanese shareholder. Harbour BioMed...

Chinese BsAb ADC developer secures a license deal with Bristol-Myers Squibb. Luckin increases subsidies for franchisees during the winter. LGES...

China's drug sector is driven by liquidity, with limited investment choices. Akeso and BeiGene are recommended as buy options, while RemeGen,...